#JAKinhibitors
There is currently no robust #clinicaltrial data confirming ruxolitinib's effectiveness for the complexity range of symptoms associated with #LongCOVID due to
- A significant concern with #JAKinhibitors is their immunosuppressive effect,
October 19, 2025 at 5:44 AM Everybody can reply
1 likes
#Medsky🧪 #IDsky #pharmasky #Publichealth This IPDMA of RCTs in adults admitted to 🏥 due to #COVID, #JAKinhibitors reduced mortality across all levels of respiratory support, independent of #dexamethasone or #tocilizumab & probably decreased serious & severe adverse events vs with no JAK inhibitors.
July 11, 2025 at 7:14 AM Everybody can reply
1 likes
#MedSky🧪#IDSky #JAKinhibitors are used to treat #COVID19 because they can prevent phosphorylation of key proteins involved in the signal transduction that leads to immune activation and inflammation (e.g cellular response to proinflammatory cytokines such as IL6)

www.science.org/doi/10.1126/...
A specific phosphorylation-dependent conformational switch in SARS-CoV-2 nucleocapsid protein inhibits RNA binding
Phosphorylation of SARS-CoV-2 nucleocapsid protein induces conformational changes that inhibit RNA binding and release bound RNA.
www.science.org
August 6, 2024 at 8:33 PM Everybody can reply